Scientific Program

Will be Announced on a Later Date

• Origin of Antiphospholipid Antibodies
• Genetics of Antiphospholipid Antibodies/Syndrome
• Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis
• Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity
• Target Cells and Receptors that Interact with Antiphospholipid Antibodies
• Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome
• Impact of Antiphospholipid Syndrome in General Population with Thrombosis and Pregnancy Morbidity
• Association with Antiphospholipid Syndrome and Other Systemic Autoimmune Diseases (Systemic Lupus Erythematosis, Rheumatoid Arthritis)
• Microangiopathic and Catastrophic Antiphospholipid Syndrome
• Impact of Pediatric APS in Children with Thrombosis
• Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests
• Strengths and Limitations of the Current Classification Criteria
• Disease Measurement Criteria in Antiphospholipid Syndrome
• Most Recent Strategies in the Treatment of Thrombosis in General Population
• Current Treatment strategies for Non-obstetric Antiphospholipid Syndrome
• Current Treatment strategies for Obstetric Antiphospholipid Syndrome
• Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies with New Generation Oral Anticoagulants, B-cell inhibition, Complement Inhibition, Hydroxychloroquine, Statins, Peptide Therapy, and others)
• Antiphospholipid Antibodies, Antiphospholipid Syndrome (APS), and Obstetric APS for Patients

Selected Sessions

The Scientific Planning Committee will chair sessions on their areas of expertise. The meeting will produce a state-of-the-art APS book, entitled “APS – Current Research Highlights and Clinical Insights” to be published in early 2017. Selected sessions include:

HISTORY OF ANTIPHOSPHOLIPID SYNDROME Overview of the Last 31 years and 15 International Congresses on Antiphospholipid Antibodies Chairs: Michael D Lockshin, Nigel E. Harris BASIC SCIENCE ASPECTS OF ANTIPHOSPHOLIPID SYNDROME What are the Natural Proteins Involved in Antiphospholipid Syndrome? Chairs: Philip G. de Groot, Steve Krilis What is the Origin of Antiphospholipid Antibodies? Chairs: Rohan Willis, Joyce Rauch What is the Genetics of Antiphospholipid Antibodies/Syndrome? Chair: Thomas Ortel What is the Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis? Chairs: Rohan Willis, Philip G. de Groot, Steve Krilis What is the Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity? Chairs: Vikki Abrahams, Jane Salmon CLINICAL & DIAGNOSTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME What are the Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome? Chairs: Stephane Zuily, Roger A. Levy, Denis Wahl, Michael Lockshin What are Microangiopathic and Catastrophic Antiphospholipid Syndrome? Chairs: Gerard Espinosa, Ricard Cervera What are the Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests? Chair: Laura Bertolaccini What are the Disease and Risk Measurement Criteria in Antiphospholipid Syndrome? Chair: Mary-Carmen Amigo

THERAPEUTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME Prevention & Treatment of Thrombotic Antiphospholipid Syndrome Chairs: Guillermo Ruiz-Irastorza, Mark Crowther Prevention & Treatment of Obstetric Antiphospholipid Syndrome Chairs: Ware Branch, Guilherme de Jesus Treatment of Non-Criteria Manifestations and/or Difficult Clinical Situations in Antiphospholipid Syndrome Chair: Danieli Andrade, Renata Rosa Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Update Chair: Doruk Erkan 15th INTERNATIONAL CONGRESS ON ANTIPHOSPHOLIPID ANTIBODIES TASK FORCE REPORTS Task Force Report on Antiphospholipid Syndrome Diagnostic and Classification Criteria Chairs: Doruk Erkan, Medha Barbhaiya, Karen Costenbader Task Force Report on Pediatric Antiphospholipid Syndrome Chairs: Barry Myones, Tadej Avcin Task Force on Catastrophic Antiphospholipid Syndrome Chairs: Ricard Cervera, Gerard Espinosa Task Force Report on Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies) Chairs: Danieli Andrade, Maria G. Tektonidou ANTIPHOSPHOLIPID SYNDROME FOR PATIENTS What Should Patients Know About Antiphospholipid Antibodies and Antiphospholipid Syndrome? Chairs: Doruk Erkan, Michael Lockshin What Should Patients Know About Obstetric Antiphospholipid Syndrome? Chairs: Lisa Sammaritano, Roger A. Levy